Cited by

• Catalase overexpression in aortic smooth muscle prevents pathological mechanical changes underlying abdominal aortic aneurysm formation.

  Maiellaro-Rafferty K, Weiss D, Joseph G, Wan W, Gleason RL, Taylor WR. Maiellaro-Rafferty K, et al. Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H355-62. doi: 10.1152/ajpheart.00040.2011. Epub 2011 May 6. Am J Physiol Heart Circ Physiol. 2011. PMID: 21551275 Free PMC article.
• Biomarkers of AAA progression. Part 1: extracellular matrix degeneration.

  Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW. Hellenthal FA, et al. Nat Rev Cardiol. 2009 Jul;6(7):464-74. doi: 10.1038/nrcardio.2009.80. Epub 2009 May 26. Nat Rev Cardiol. 2009. PMID: 19468292 Review.
• Intracranial and abdominal aortic aneurysms: similarities, differences, and need for a new class of computational models.

  Humphrey JD, Taylor CA. Humphrey JD, et al. Annu Rev Biomed Eng. 2008;10:221-46. doi: 10.1146/annurev.bioeng.10.061807.160439. Annu Rev Biomed Eng. 2008. PMID: 18647115 Free PMC article. Review.
• FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.

  Moñux G, Zamorano-León JJ, Marqués P, Sopeña B, García-García JM, Laich de Koller G, Calvo-Rico B, García-Fernandez MA, Serrano J, López-Farré A. Moñux G, et al. Br J Clin Pharmacol. 2017 Dec;83(12):2661-2670. doi: 10.1111/bcp.13383. Epub 2017 Aug 27. Br J Clin Pharmacol. 2017. PMID: 28735510 Free PMC article.
• Mechanisms of oxidative stress in human aortic aneurysms--association with clinical risk factors for atherosclerosis and disease severity.

  Guzik B, Sagan A, Ludew D, Mrowiecki W, Chwała M, Bujak-Gizycka B, Filip G, Grudzien G, Kapelak B, Zmudka K, Mrowiecki T, Sadowski J, Korbut R, Guzik TJ. Guzik B, et al. Int J Cardiol. 2013 Oct 3;168(3):2389-96. doi: 10.1016/j.ijcard.2013.01.278. Epub 2013 Mar 15. Int J Cardiol. 2013. PMID: 23506637 Free PMC article.